02185 BIOHEART-B
- 1.470
- +0.070+5.00%
BIOHEART-B News
Shanghai Bio-heart Biological Technology Shrinks H1 Loss
Bai Xin An -B (02185) announced its interim performance. The loss attributable to the parent company's owners was 25.83 million yuan, with a year-on-year narrowing of 70%.
Baixinan-B (02185) announced its mid-term performance in 2024, with R&D spending of approximately RMB 21.8 million (adjusted for inflation). ...
Express News | Shanghai Bio-Heart Biological Technology H1 Net Income RMB -28.3 Million
Express News | Shanghai Bio-Heart Biological Technology H1 Capex RMB 19.8 Million
Express News | Shanghai Bio-Heart Biological Technology H1 EPS RMB -0.11
BIOHEART-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
Board of directors meeting of Baixinan-B (02185.HK) will be held on August 19 to approve the interim performance.
Baixinan-B (02185.HK) announced on August 7th that the board of directors will hold a meeting on August 19, 2024 to review and approve the mid-year performance of the company and its subsidiaries for the six months ending June 30, 2024, and consider the payment of interim dividends (if any).
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
Yiqing Chen and Yifei Jiang have been appointed as independent non-executive directors of Baixin Security-B (02185).
Pakson International Company Limited (02185) announced that Mr. Chan Shang Wei and Mr. Zheng Rongyao have resigned from their positions as...
Baixinan-B proposes to appoint Chen Yiqing as an independent non-executive director
Baixinan-B (02185) issued an announcement. The board of directors has been informed by Chen Shangwei and Zheng Rongyao that they will resign as independent non-executive directors to spend more time on their other work. Their resignations will take effect after the AGM. Until then, Chen Shangwei and Zheng Rongyao will continue to perform their duties as independent non-executive directors. Following the resignation of Chan Sheung-wai and Cheng Wing-yiu, Chan Sheung-wai will no longer serve as Chairman of the Audit Committee and a member of the Remuneration Committee and Nomination Committee, and Cheng Wing-yiu will no longer serve as a member of the Audit Committee and Remuneration Committee. After considering the recommendation of the Nomination Committee, the Director
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
BIOHEART-B: 2023 ANNUAL REPORT
Baixinan-B (02185.HK) lost about 189 million yuan in 2023
Gelonghui, March 25 | Baixinan-B (02185.HK) announced that for the year ended December 31, 2023, the Group's net loss was approximately RMB 188.8 million, a decrease of 18.2% from approximately RMB 230.9 million in 2022. R&D expenditure for the year ended 31 December 2023 was approximately RMB 111.7 million, a decrease of 29.2% from approximately RMB 157.8 million recorded in 2022. As of December 31, 2023, the net asset liability ratio was 5.4% (2022:6.8%).
BIOHEART-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31, 2023
Baixinan-B (02185.HK) plans to hold a board meeting on March 25 to approve the annual results
Gelonghui, March 13 | Baixinan-B (02185.HK) announced that the company will hold a board meeting on March 25, 2024 (Monday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the proposed payment of a final dividend (if any).
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Analysis
Price Target
No Data
No Data